1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014

Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Glioblastoma Multiforme (GBM) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Glioblastoma Multiforme (GBM). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Glioblastoma Multiforme (GBM). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Recurrent Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Recurrent Glioblastoma Multiforme (GBM) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Recurrent Glioblastoma Multiforme (GBM) 24
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Recurrent Glioblastoma Multiforme (GBM) 33
Mar 06, 2014: SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc.'s VAL-083 Clinical Trial 33
Mar 04, 2014: Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma 33
Jan 13, 2014: Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma 34
Jan 07, 2014: Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco 34
Dec 23, 2013: ImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent Glioblastoma 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
F. Hoffmann-La Roche Ltd. 36
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 36
Novartis AG 38
Clinical Trial Overview of Novartis AG 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Merck and Co., Inc. 40
Clinical Trial Overview of Merck and Co., Inc. 40
AstraZeneca PLC 41
Clinical Trial Overview of AstraZeneca PLC 41
Eli Lilly and Company 42
Clinical Trial Overview of Eli Lilly and Company 42
Eisai Co., Ltd. 43
Clinical Trial Overview of Eisai Co., Ltd. 43
Medicenna Therapeutics, Inc 44
Clinical Trial Overview of Medicenna Therapeutics, Inc 44
E. Merck KG 45
Clinical Trial Overview of E. Merck KG 45
Bristol-Myers Squibb Company 46
Clinical Trial Overview of Bristol-Myers Squibb Company 46
Clinical Trial Overview of Top Institutes / Government 47
National Cancer Institute 47
Clinical Trial Overview of National Cancer Institute 47
The University of Texas M. D. Anderson Cancer Center 49
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 49
Duke University 50
Clinical Trial Overview of Duke University 50
Massachusetts General Hospital 51
Clinical Trial Overview of Massachusetts General Hospital 51
European Organization for Research and Treatment of Cancer 52
Clinical Trial Overview of European Organization for Research and Treatment of Cancer 52
Rigshospitalet 53
Clinical Trial Overview of Rigshospitalet 53
Cedars-Sinai Medical Center 54
Clinical Trial Overview of Cedars-Sinai Medical Center 54
Case Comprehensive Cancer Center 55
Clinical Trial Overview of Case Comprehensive Cancer Center 55
University of Zurich 56
Clinical Trial Overview of University of Zurich 56
Five Key Clinical Profiles 57
Appendix 152
Abbreviations 152
Definitions 152
Research Methodology 153
Secondary Research 153
About GlobalData 154
Contact Us 154
Disclaimer 154
Source 155

List of Tables
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 36
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 38
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 39
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 40
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 41
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 42
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014* 43
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medicenna Therapeutics, Inc, 2014* 44
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 45
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 46
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 47
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 49
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2014* 50
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 51
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2014* 52
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 53
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cedars-Sinai Medical Center, 2014* 54
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 55
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Zurich, 2014* 56

List of Figures
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Recurrent Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Recurrent Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Recurrent Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 153

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.